
The BioPharm Brief: FDA Rejects Ivonescimab, Gazyva Becomes the First Approved pMN Therapy, and a Nanobody Approval in Myasthenia Gravis
FDA issues a complete response letter for Summit Therapeutics’ PD-1/VEGF bispecific ivonescimab in EGFR-mutated non-small cell lung cancer, approves Roche’s obinutuzumab (Gazyva) for primary membranous nephropathy, and approves AstraZeneca’s nanobody C5 inhibitor gefurulimab (Klygefa) for generalized myasthenia gravis.
<iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8977581/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>
Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today is all FDA decisions: a rejection that puts overall survival at center stage, a first-ever approval in a rare kidney disease, and a new format for complement inhibition.
First,
Next,
And finally,
That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.
Key takeaways
- Survival bar: The ivonescimab rejection shows FDA requiring an overall survival benefit, not just progression-free survival, in this lung cancer setting.
- First in class for the indication: Gazyva gives patients with primary membranous nephropathy their first approved therapy.
- New formats: Klygefa brings nanobody-based C5 inhibition to patients as an at-home, once-weekly injection.
Related to this article









